Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Fatigue 7Neoplasms 4Brain Neoplasms 3Depression 2Asthenia 2Recurrence 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Meningioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Methylphenidate × Clear all
NCT03525873 2026-04-15

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
212 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡